Truist Financial Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $520
Truist Financial Sticks to Its Buy Rating for Intuitive Surgical (ISRG)
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $480 From $440
Deutsche Bank Raises Intuitive Surgical Price Target to $445 From $390, Maintains Hold Rating
Intuitive Surgical (ISRG) Receives a Buy From BTIG
BTIG Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $469
Barclays Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $490
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Outperform Rating Reaffirmed for Intuitive Surgical on Strong Q2 2024 Performance and Da Vinci 5 Launch Success
JPMorgan Raises Price Target on Vertex Pharmaceuticals to $505 From $450, Maintains Overweight Rating
Piper Sandler Maintains Overweight on Intuitive Surgical, Raises Price Target to $495
Vertex Pharmaceuticals Analyst Ratings
Piper Sandler Remains a Buy on Intuitive Surgical (ISRG)
JPMorgan Adjusts Price Target on Intuitive Surgical to $495 From $475, Maintains Overweight Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
Strong Performance and Growth Prospects Underpin Buy Rating for Intuitive Surgical
Barclays Maintains Overweight on Intuitive Surgical, Raises Price Target to $490
Intuitive Surgical Analyst Ratings
B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $40